TL;DR: Aetna modified CPB 0997 covering anifrolumab-fnia (Saphnelo) for systemic lupus erythematosus, effective September 26, 2025. Here's what billing teams need to do.
Aetna updated its anifrolumab-fnia Saphnelo coverage policy under CPB 0997, reaffirming the concurrent standard treatment requirements for HCPCS J0491 (injection, anifrolumab-fnia, 1 mg). If your practice or infusion center bills J0491 alongside administration codes CPT 96365–96368, this policy directly affects your prior authorization workflow and your claim denial risk starting September 26, 2025.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna |
| Policy | Anifrolumab-fnia (Saphnelo) — CPB 0997 |
| Policy Code | CPB 0997 |
| Change Type | Modified |
| Effective Date | September 26, 2025 |
| Impact Level | High |
| Specialties Affected | Rheumatology, Infusion Centers, Specialty Pharmacy, Internal Medicine |
| Key Action | Audit all active Saphnelo prior authorizations for exclusion criteria compliance before September 26, 2025 |
Aetna Anifrolumab-fnia (Saphnelo) Coverage Criteria and Medical Necessity Requirements 2025
Aetna's coverage policy for Saphnelo requires precertification on all commercial plans — no exceptions. Call (866) 752-7021 or fax (888) 267-3277 to submit. Statement of Medical Necessity forms are available through Aetna's Specialty Pharmacy Precertification portal.
There are two gates your patient must clear for initial approval. First, the member must test positive for autoantibodies relevant to SLE before starting therapy. Acceptable autoantibodies include ANA, anti-dsDNA, anti-Sm, antiphospholipid antibodies, and complement proteins. No documented positive autoantibody result means no medical necessity, full stop.
Second, the member must already be receiving standard SLE treatment. Aetna accepts glucocorticoids (prednisone, methylprednisolone, dexamethasone), antimalarials (hydroxychloroquine), or immunosuppressants (azathioprine, methotrexate, mycophenolate, cyclosporine, cyclophosphamide) — alone or in combination. This is a hard background therapy requirement. A patient who starts Saphnelo cold, without concurrent standard treatment, will be denied.
For reauthorization, the standard is lower but still meaningful. The member must show low disease activity or improvement in signs and symptoms. Document this clearly in the chart before you submit for continuation. Vague notes like "patient tolerating medication" won't hold up if Aetna audits the reimbursement request.
Aetna's prior authorization requirement also triggers its Site of Care Utilization Management Policy. Before billing CPT 96365 or J0491, confirm that the infusion site is approved under Aetna's Site of Care for Specialty Drug Infusions policy. Billing from a non-approved site is a clean path to a claim denial.
Aetna Saphnelo Exclusions and Non-Covered Indications
This is where the real billing risk lives. Aetna excludes three specific situations from coverage. Get these wrong and you're looking at a denial that will be hard to appeal.
Exclusion one: Severe active lupus nephritis at initiation. If a patient is starting Saphnelo for the first time and has severe active lupus nephritis, Aetna will not cover it. This is an initiation-specific exclusion — a patient who develops lupus nephritis after already being stable on Saphnelo is a different clinical situation, but document that carefully.
Exclusion two: Severe active CNS lupus at initiation. This exclusion is broad. It covers seizures attributed to CNS lupus, psychosis, organic brain syndrome, cerebritis, and CNS vasculitis that require therapeutic intervention before Saphnelo starts. The key phrase is "requiring therapeutic intervention." If your patient has any of these active CNS manifestations at the time of initiation, Aetna will deny the claim. The ICD-10 codes M32.0 through M32.9 all carry a notation that CNS lupus is not covered — flag this in your billing system.
Exclusion three: Combination with other biologics. Saphnelo combined with any other biologic is not covered. This is a common scenario in complex SLE patients. If your patient is also receiving belimumab (Benlysta — see Aetna CPB 0818) or any other biologic, Saphnelo billing will be denied. Verify the full medication list before submitting.
All other indications not explicitly covered in Section II of the policy are considered experimental, investigational, or unproven. Aetna anifrolumab billing outside active SLE — including subacute cutaneous lupus erythematosus coded as L93.1 — is not an approved indication and is considered experimental, investigational, or unproven under CPB 0997.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Active SLE with positive autoantibodies + background standard therapy | Covered | J0491, M32.0–M32.9, CPT 96365–96368 | Prior auth required; site of care policy applies |
| Continuation of Saphnelo with documented positive clinical response | Covered | J0491, M32.0–M32.9 | Must show low disease activity or symptom improvement at reauth |
| Severe active lupus nephritis at initiation | Not Covered | M32.1 (lupus nephritis) | Exclusion applies only at initiation; document timing carefully |
| Severe active CNS lupus at initiation (seizures, psychosis, cerebritis, CNS vasculitis) | Not Covered | M32.0–M32.9 | Broad exclusion; any CNS lupus requiring intervention at initiation is excluded |
| Saphnelo combined with other biologics | Not Covered | J0491 | Combination biologic therapy is excluded regardless of indication |
| Subacute cutaneous lupus erythematosus (L93.1) alone | Experimental / Unproven | L93.1 | Not an approved indication under CPB 0997 |
| Lupus anticoagulant syndrome (D68.62) alone | Experimental / Unproven | D68.62 | Not an approved indication under CPB 0997 |
| Any SLE indication without documented positive autoantibodies | Not Covered | M32.0–M32.9 | Autoantibody documentation is a hard prerequisite |
Aetna Saphnelo Billing Guidelines and Action Items 2025
These are the steps your team needs to complete before the effective date of September 26, 2025.
| # | Action Item |
|---|---|
| 1 | Audit all active Saphnelo prior authorizations now. Pull every open Saphnelo auth and check it against the three exclusion criteria. If any active patient has severe active lupus nephritis, severe active CNS lupus, or concurrent biologic therapy, flag the case for your medical director and compliance officer before September 26, 2025. |
| 2 | Update charge capture to include autoantibody documentation requirements. Build a hard stop in your prior auth intake workflow. Before any team member submits for J0491, the chart must include documented autoantibody test results (ANA, anti-dsDNA, anti-Sm, antiphospholipid antibodies, or complement proteins). Missing this is the single most common reason for denial on biologics with serology requirements. |
| 3 | Verify background therapy documentation. Every Saphnelo claim needs evidence that the patient is receiving at least one standard SLE therapy. Document the concurrent medication in the auth request — don't assume Aetna will infer it from the diagnosis codes. Accepted background therapies map to specific HCPCS codes: prednisone (J7512), methylprednisolone (J1020, J1030, J1040, J2920, J2930), dexamethasone (J1094, J1100, J8540), azathioprine (J7500, J7501), methotrexate (J8610, J8611, J8612, J9250, J9260), mycophenolate (J7514, J7517, J7519, J7528), cyclosporine (J7502, J7515, J7516), cyclophosphamide (J8530, J9070, J9073, J9074, J9075, J9076). |
| 4 | Confirm site of care approval before billing. Aetna's Site of Care Utilization Management Policy applies to Saphnelo infusions. If your patient is receiving Saphnelo at a hospital outpatient department or infusion suite, confirm that site is approved for specialty drug infusions under Aetna's policy. Aetna lists both intravenous infusion administration codes (CPT 96365–96368) and chemotherapy administration codes (CPT 96413–96417) as related to this policy. |
| 5 | Set up reauthorization tracking with documented clinical response. Continuation approvals require evidence of low disease activity or symptom improvement. At each clinical visit, ensure the treating physician documents a response assessment — not just "patient continues Saphnelo." When you submit for reauth, attach that documentation directly. Aetna Saphnelo reimbursement on continuation claims gets denied when the clinical response note is absent or generic. |
| 6 | Talk to your compliance officer if you have patients on combination biologic therapy. The exclusion for Saphnelo combined with other biologics is absolute in this policy. If you have SLE patients on both Saphnelo and belimumab (Benlysta), there is no coverage pathway under CPB 0997. Your compliance officer and medical director need to weigh in on how to handle those cases before the effective date. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Anifrolumab-fnia (Saphnelo) Under CPB 0997
Covered HCPCS Code (When Selection Criteria Are Met)
| Code | Type | Description |
|---|---|---|
| J0491 | HCPCS | Injection, anifrolumab-fnia, 1 mg |
Other CPT Codes Related to This Policy (Administration)
| Code | Type | Description |
|---|---|---|
| 96365 | CPT | Intravenous infusion administration |
| 96366 | CPT | Intravenous infusion administration |
| 96367 | CPT | Intravenous infusion administration |
| 96368 | CPT | Intravenous infusion administration |
| 96413 | CPT | Chemotherapy administration |
| 96414 | CPT | Chemotherapy administration |
| 96415 | CPT | Chemotherapy administration |
| 96416 | CPT | Chemotherapy administration |
| 96417 | CPT | Chemotherapy administration |
Other HCPCS Codes Related to This Policy (Background Therapies)
| Code | Type | Description |
|---|---|---|
| J1020 | HCPCS | Injection, methylprednisolone acetate, 20 mg |
| J1030 | HCPCS | Injection, methylprednisolone acetate, 40 mg |
| J1040 | HCPCS | Injection, methylprednisolone acetate, 80 mg |
| J1094 | HCPCS | Injection, dexamethasone acetate, 1 mg |
| J1100 | HCPCS | Injection, dexamethasone sodium phosphate, 1 mg |
| J2920 | HCPCS | Injection, methylprednisolone sodium succinate, up to 40 mg |
| J2930 | HCPCS | Injection, methylprednisolone sodium succinate, up to 125 mg |
| J7500 | HCPCS | Azathioprine, oral, 50 mg |
| J7501 | HCPCS | Azathioprine, parenteral, 100 mg |
| J7502 | HCPCS | Cyclosporine, oral, 100 mg |
| J7509 | HCPCS | Methylprednisolone oral, per 4 mg |
| J7512 | HCPCS | Prednisone, immediate release or delayed release, oral, 1 mg |
| J7514 | HCPCS | Mycophenolate mofetil (myhibbin), oral suspension, 100 mg |
| J7515 | HCPCS | Cyclosporine, oral, 25 mg |
| J7516 | HCPCS | Cyclosporin, parenteral, 250 mg |
| J7517 | HCPCS | Mycophenolate mofetil, oral, 250 mg |
| J7519 | HCPCS | Injection, mycophenolate mofetil, 10 mg |
| J7528 | HCPCS | Mycophenolate mofetil, for suspension, oral, 100 mg |
| J8530 | HCPCS | Cyclophosphamide, oral, 25 mg |
| J8540 | HCPCS | Dexamethasone, oral, 0.25 mg |
| J8610 | HCPCS | Methotrexate, oral, 2.5 mg |
| J8611 | HCPCS | Methotrexate (jylamvo), oral, 2.5 mg |
| J8612 | HCPCS | Methotrexate (xatmep), oral, 2.5 mg |
| J9070 | HCPCS | Cyclophosphamide, 100 mg |
| J9073 | HCPCS | Injection, cyclophosphamide (ingenus), 5 mg |
| J9074 | HCPCS | Injection, cyclophosphamide (sandoz), 5 mg |
| J9075 | HCPCS | Injection, cyclophosphamide, not otherwise specified, 5 mg |
| J9076 | HCPCS | Injection, cyclophosphamide (baxter), 5 mg |
| J9250 | HCPCS | Methotrexate sodium, 5 mg |
| J9255 | HCPCS | Injection, methotrexate (accord), not therapeutically equivalent to J9250 or J9260, 50 mg |
| J9260 | HCPCS | Methotrexate sodium, 50 mg |
Key ICD-10-CM Diagnosis Codes
| Code | Description | Coverage Note |
|---|---|---|
| M32.0 | Systemic lupus erythematosus (SLE) [not covered for severe active central nervous system (CNS) lupus] | Covered for active SLE; CNS lupus manifestations not covered |
| M32.1 | Systemic lupus erythematosus (SLE) [not covered for severe active central nervous system (CNS) lupus] | Covered for active SLE; CNS lupus manifestations not covered |
| M32.2 | Systemic lupus erythematosus (SLE) [not covered for severe active central nervous system (CNS) lupus] | Covered for active SLE; CNS lupus manifestations not covered |
| M32.3 | Systemic lupus erythematosus (SLE) [not covered for severe active central nervous system (CNS) lupus] | Covered for active SLE; CNS lupus manifestations not covered |
| M32.4 | Systemic lupus erythematosus (SLE) [not covered for severe active central nervous system (CNS) lupus] | Covered for active SLE; CNS lupus manifestations not covered |
| M32.5 | Systemic lupus erythematosus (SLE) [not covered for severe active central nervous system (CNS) lupus] | Covered for active SLE; CNS lupus manifestations not covered |
| M32.6 | Systemic lupus erythematosus (SLE) [not covered for severe active central nervous system (CNS) lupus] | Covered for active SLE; CNS lupus manifestations not covered |
| M32.7 | Systemic lupus erythematosus (SLE) [not covered for severe active central nervous system (CNS) lupus] | Covered for active SLE; CNS lupus manifestations not covered |
| M32.8 | Systemic lupus erythematosus (SLE) [not covered for severe active central nervous system (CNS) lupus] | Covered for active SLE; CNS lupus manifestations not covered |
| M32.9 | Systemic lupus erythematosus (SLE) [not covered for severe active central nervous system (CNS) lupus] | Covered for active SLE; CNS lupus manifestations not covered |
| L93.1 | Subacute cutaneous lupus erythematosus | Not an approved indication under CPB 0997 |
| D68.62 | Lupus anticoagulant syndrome (Rowell syndrome) | Not an approved indication under CPB 0997 |
Get the Full Picture for CPT 96365
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.